Pressure on earnings from revisions to systems such as dispensing fees and long-term care fees
First written in FY2022. 7 of 12 entries say "Materialised", first in FY2023-Q2. Latest entry: 2026-08-10.
Miahelsa Holdings moved to the "Worse" side of this theme in 2026, 1 year after the typical company in this theme (2025).
The whole theme swung hardest in 2026: 7 of 16 companies on the "Worse" side.
6 other companies' latest entry also says "Materialised".
- FY2026-H1MaterialisedAnnual report
「Although the company worked to obtain add-ons for dispensing technical fees and pharmaceutical management fees, the prescription unit price declined because the proportion of medical-mall-type pharmacies, which have lower prescription unit prices, increased within the Group's dispensing pharmacy portfolio, in addition to the impact of the drug-price revisions implemented in April 2025.」
The impact of the April 2025 drug-price revisions materialized as a decline in the prescription unit price. The company also identifies the increased proportion of medical-mall-type pharmacies as a factor behind the decline. - FY2025MitigatedAnnual report
「The company worked to strengthen initiatives related to the generic-drug dispensing-system add-on and enhance services as a family pharmacy, but the prescription unit price declined due to the impact of the revisions to dispensing reimbursement rates and drug prices implemented in April 2024.」
The prescription unit price declined following the April 2024 revisions, while the company continues to strengthen the generic-drug add-on and family-pharmacy services as countermeasures. - FY2025-H1MitigatedAnnual report
「The prescription unit price declined due to the impact of the revisions to dispensing reimbursement rates and drug prices implemented in April 2024. However, the impact was kept to a minimum because the number of prescriptions for high-priced medicines increased, the company pursued the generic-drug dispensing-system add-on and enhanced services as a family pharmacy, and it worked to obtain additional technical fees.」
The impact of the April 2024 revisions to dispensing reimbursement rates and drug prices materialized as a decline in the prescription unit price, but the company states that the impact was kept to a minimum through efforts to obtain additional reimbursements and other measures. - FY2024-Q3RestatedAnnual report
「Although the prescription unit price was affected by the drug-price revisions implemented in April 2023, it increased as the number of prescriptions for patients with infectious diseases and high-priced medicines rose, and the company continued to enhance services as a family pharmacy and strengthen its generic-drug dispensing-system add-on to obtain additional dispensing technical fees.」
The impact of the drug-price revisions continues, but the company reiterates that the prescription unit price increased due to high-priced medicines, family-pharmacy services and the generic-drug dispensing-system add-on. - FY2024-Q2MitigatedAnnual report
「Although the prescription unit price was affected by the drug-price revisions implemented in April 2023, it increased as the number of prescriptions for high-priced medicines rose and the company worked to obtain add-on dispensing technical fees by strengthening its generic-drug dispensing-system add-on and enhancing services as a family pharmacy.」
Although the April 2023 drug-price revisions had an impact, the prescription unit price increased due to high-priced medicines, the generic-drug dispensing-system add-on and family-pharmacy services, indicating progress in addressing the impact. - FY2024-Q1MaterialisedAnnual report
「The prescription unit price declined due to the impact of the drug-price revisions implemented in April 2023. However, the impact of the revisions was kept to a minimum because the number of prescriptions for high-priced medicines increased, services as a family pharmacy were enhanced, and the company worked to obtain add-on dispensing technical fees.」
The April 2023 drug-price revisions resulted in a decline in the prescription unit price. However, the company states that the impact was kept to a minimum through enhanced services and the acquisition of add-ons. - FY2023-Q2MaterialisedAnnual report
「The company continued efforts to obtain add-on technical fees by strengthening its generic-drug dispensing-system add-on, enhancing its home healthcare services and improving services as a family pharmacy. However, the prescription unit price declined due to the impact of the revisions to dispensing reimbursement rates and drug prices implemented in April 2022.」
The impact of the April 2022 revisions to dispensing reimbursement rates and drug prices materialized as a decline in the prescription unit price. - FY2022First statedAnnual report
「Because reductions in dispensing and care-service reimbursement rates resulting from the country's fiscal difficulties would significantly affect the Group's operations by reducing revenue from its dispensing pharmacy and care businesses, we recognize the need to obtain reimbursement add-ons promptly by responding early to government policy. We also recognize the need to increase revenue by providing pharmaceutical, care and childcare services on a one-stop basis.」
The company identifies reductions in dispensing and care-service reimbursement rates resulting from the country's fiscal position and policy changes as an external risk that could reduce revenue, presented separately for the first time.